Antibody-drug conjugates (ADCs) company CCO departs Nov 01, 2022 - WALTHAM, Mass.-- ImmunoGen, Inc. , involved in the field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Kristen Harrington-Smith, Senior Vice President and Chief Commercial Officer (CCO), will be departing the Company.
https://www.biospace.com/article/releases/immunogen-announces-departure-of-chief-commercial-officer-november-01-2022/